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Abstract
Background: While it is well known that bradykinin B2 agonists increase plasma protein
extravasation (PPE) in brain tumors, the bradykinin B1 agonists tested thus far are unable to
produce this effect. Here we examine the effect of the selective B1 agonist bradykinin (BK) Sar-[D-
Phe8]des-Arg9BK (SAR), a compound resistant to enzymatic degradation with prolonged activity
on PPE in the blood circulation in the C6 rat glioma model.
Results: SAR administration significantly enhanced PPE in C6 rat brain glioma compared to saline
or BK (p < 0.01). Pre-administration of the bradykinin B1 antagonist [Leu8]-des-Arg (100 nmol/Kg)
blocked the SAR-induced PPE in the tumor area.
Conclusions: Our data suggest that the B1 receptor modulates PPE in the blood tumor barrier
of C6 glioma. A possible role for the use of SAR in the chemotherapy of gliomas deserves further
study.
Background
Bradykinin (BK) is a vasoactive peptide released from its
high molecular weight precursors, the kininogens,
through the action of serine proteases, the kallikreins,
playing a crucial role in pathologic processes like inflam-
mation, infectious diseases, and cancer [1,2]. The brain
and spinal cord contain all of the components necessary
for kinin formation and action. In addition, central nerv-
ous system traumas lead to kinin formation [3]. BK type-
1 (B1) receptors are mostly expressed in pathological or
stressful situations related to tissue damage [1,2] includ-
ing tumors [2]. The BK type-2 (B2) receptor is defined as
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a constitutive one, being normally encountered in many
tissues, including the brain [2,4]. It is well known that the
blood-brain barrier (BBB) in brain tumor regions (also
called blood tumor barrier, or BTB) shows different
plasma protein extravasation (PPE) characteristics when
compared with the BBB of normal brain tissue and this
effect is particularly related to the increase of B2 receptors
[5-7]. In animal models, B2 receptor agonists like Cere-
port® (RMP-7) have been used by the intracarotid route to
enhance the delivery of chemotherapeutic agents to the
brain tumor area [7-9]. B1 receptor agonists with low met-
abolic resistance (MR) have already been unsuccessfully
tested on PPE extravasation through the BTB in brain
tumors [8,9]. The B1 receptor agonist, Sar-[D-Phe8]des-
Arg9BK (SAR), shows some resistance to enzymatic degra-
dation that is due to the addition of amino acids to the
amino-terminal portion of the molecule [10]. Thus, it is
possible that SAR could be successful in promoting PPE
through the BTB, having potential uses in enhancing the
delivery of chemotherapeutic agents to brain tumors. In
order to test this hypothesis, we investigated the effect of
SAR on PPE using the rat C6 glioma model [11].
Results
Eighty percent of C6-inoculated animals developed brain
tumors after a period of 30 days (data not shown). We
determined PPE in experimental groups of animals
treated with bradykinin (BK), the BK receptor B1 agonist
(SAR) or the BK receptor B1 antagonist (LEU) (Fig. 1). PPE
in the tumor area of C6-inoculated animals was 22.8 ± 6.4
µg EB/g dry tissue, a value that did not differ from those
observed in tumor-free animals inoculated with vehicle
only (26.3 ± 16.7 µg EB/g dry tissue), or inoculated with
cell vehicle plus SAR (23.2 ± 9.8 µg EB/g dry tissue). Injec-
tion of BK into C6-inoculated animals also did not change
the tumor PPE (30.6 ± 10.9 µg EB/g dry tissue). It is
important to note that in all groups the left (non-inocu-
lated) hemispheres presented PPE values similar to those
of the right (inoculated) hemisphere in the control ani-
mals. However, SAR significantly increased PPE in the
tumor area of C6-inoculated animals (91.9 µg EB/g dry
tissue ± 7.9) (p < 0.01). This effect was abolished, with a
return to basal levels, by pre-treatment of the animals with
the BK receptor B1 antagonist LEU (35.8 ± 8.6 µg EB/g dry
tissue). The effect of SAR in increasing PPE in C6-inocu-
lated right hemispheres (91.9 µg EB/g dry tissue ± 7.9) was
also observed (t = 24.9, p < 0.001) when compared to the
contralateral non-tumoral hemisphere (21.7 µg EB/g dry
tissue ± 3.0, n = 6) (Fig. 2).
Discussion
We demonstrate here that the selective B1 receptor agonist
SAR [16] enhances PPE in C6 glioma without affecting the
normal brain parenchyma. It has been previously shown
that SAR at 100 nmol/Kg also does not alter the systemic
blood pressure of rats [17]. The effect of SAR was blocked
by pre-treatment with the selective B1 receptor antagonist
LEU, suggesting that PPE can be modulated by B1 recep-
tors in the glioma model of C6-inoculated rats.
It was recently described that gliomas may express both
B1 and B2 BK receptors, with B2 being located closer to
the periphery of the tumor cells while B1 was observed
throughout the cell [18]. In view of their effects on vascu-
lar dilatation and blood flow, bradykinin receptor ago-
nists have been tested in the chemotherapy of brain
tumors [18,19], whereas bradykinin itself was less used
for this purpose [6,7] due to its lower efficacy and shorter
blood half-life. In contrast to other authors [6,9] we did
not observe an effect of BK by itself in enhancing BBB or
BTB permeability. Fast BK degradation could account for
this difference since we used a femoral vein, whereas other
authors used more proximal accesses like the carotid
artery [6,9]. The B2 receptor agonist RMP-7 (Cereport®)
has been successfully employed to enhance BTB permea-
bility to chemotherapeutic agents [7,20], but in the ani-
mal models already tested only local or regional routes
like the carotid artery were used [20,21].
In general, B1 receptors are non-constitutive [3] and
restricted to pathologic processes including tumors or
degeneration [2]. Systemically administered metaboli-
cally resistant B1 receptor agonists may be useful to
increase chemotherapy levels at the target site, with higher
specificity and lower toxicity than B2 receptor agonists.
Thus, we believe that SAR injected together with chemo-
therapeutic agents may be useful to increase drug delivery
specifically to the brain tumor with less toxicity to non-
affected areas. Additionally, because EB circulates bound
to albumin, it is reasonable to think that SAR could
increase the delivery of several chemotherapeutic agents
of molecular weight similar to, or lower than that of albu-
min [22,23]. Although the Evans Blue method is less sen-
sitive than other labeling methods like quantitative
autoradiography, for example, we used it because it was
the only method available to us at the time of this experi-
ment. However, the Evans-Blue method is of low cost, can
be easily reproduced by other laboratories, and was sensi-
tive enough to detect differences provoked by SAR in these
experiments.
BK or BK agonists have been previously used to increase
BTB permeability but, due to their faster enzymatic degra-
dation [6,8], they were injected into the carotid artery.
However, our findings suggest, that SAR administered
intravenously remains stable and thus could be an attrac-
tive agent for the treatment of brain or even other tumors
[24,25] that express BK B1 receptors.
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Conclusions
Our data suggest that the B1 receptor modulates PPE in
the blood tumor barrier of C6 glioma. A possible role for
the systemic use of SAR in the chemotherapy of gliomas or
other CNS neoplasms deserves further study.
Methods
C6 glioma cell culture
The C6 rat glioma cell line was cultured as previously
described [12]. Briefly, cells were grown in Dulbecco's
modified Eagle medium (DMEM, Sigma, Saint Louis, MO,
USA) supplemented with 5% fetal calf serum (FCS, Culti-
lab, Brazil), 100 mg/ ml streptomycin and 100 U/ ml pen-
icillin (all from Sigma) under standard culture conditions.
Protein plasma extravasation (PPE) in the right (inoculated) hemisphere of 6 different groups of animalsFigure 1
Protein plasma extravasation (PPE) in the right (inoculated) hemisphere of 6 different groups of animals. There was a significant 
increase in PPE when the 17-day-C6-injected animals were concomitantly injected with SAR 100 nm/Kg (C6 + SAR) compared 
to the control group (C6-inoculated). Vehicle-inoculated and vehicle-inoculated + SAR (100 nm/Kg) animals did not differ from 
each other or from the control. Bradykinin (100 nm/Kg) injected through the femoral vein did not enhance BTB permeability 
(C6 inoculated + BK). However, the specific bradykinin B1 antagonist, LEU (100 nm/Kg), improved SAR-induced PPE in the 
tumor mass (C6-inoculated + LEU + SAR). *p < 0.01 compared to PPE in the C6-inoculated, vehicle-inoculated, vehicle-inocu-
lated + SAR, and C6 inoculated + BK groups and in the C6-inoculated+LEU+SAR group.
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Cells were harvested with 0.125% trypsin/0.78 mM EDTA
when they reached confluence.
Animals and tumor inoculation
Male Wistar rats (aged 3 months and weighing 250–300 g
upon arrival from the UFSC Central Animal House) were
used. The rats were maintained in a temperature- and
light-controlled vivarium (22°C; 12:12-h light:dark cycle;
lights on at 07:00 h), with food and water available ad libi-
tum. Animals were treated according to the Guidelines for
the Use of Animals of Universidade Federal de Santa Cat-
arina. Before the procedures, the rats were anesthetized
with sodium pentobarbital (50 mg/Kg body weight, i.p.)
and then injected with 1 × 106 C6 cells prepared in 5 ml
DMEM/FCS (vehicle) into the right cerebral hemisphere
using the following coordinates: 4 mm lateral from right
bregma and 4.5 mm deep from the dural surface, as previ-
ously described [14].
Pharmacological treatment and protein plasma 
extravasation (PPE) studies
Seventeen days after C6 inoculation, BBB or BTB extrava-
sations were assessed by the Evans blue (EB, Sigma)
method [14]. EB (20 mg/Kg; 25 mg/ml in 0.9% NaCl) was
administered intravenously via a femoral vein with saline
(n = 10, C6-inoculated; n = 6, control) or in combination
with 100 nmol/Kg bradykinin (RBI, USA) (n = 6, C6-inoc-
ulated) or with 100 nmol/kg of selective bradykynin B1
agonist Sar-[D-Phe8]des-Arg9BK (n = 9, C6 inoculated; n
= 6, control) (SAR, a gift from Dr Domenico Regoli, Uni-
versité de Sherbrooke, Sherbrooke, Québec, Canada). An
additional group of C6-inoculated animals (n = 6) were
treated intravenously with SAR (100 nm/Kg) 5 min after
pre-treatment with 100 nmol/Kg of the B1 receptor antag-
onist [Leu8]-des-Arg9BK (LEU, Sigma). Previous pilot
studies conduced in our laboratory (data not presented)
showed that SAR had a maximum effect at the equivalent
dose of 100 nmol/Kg. These assays also showed that LEU
at the dose used was effective in blocking the effect of SAR
effect on isolated brain parenchyma and dura-mater. Fif-
teen minutes after the treatments, rats were perfused with
4 ml/Kg 0.9% NaCl for 3 min [14] and the brains were
removed. Two cubic centimeters of tissue were removed
around the inoculation site (right hemisphere) and from
the contralateral homologous region (left hemisphere).
EB was extracted with formamide (4 ml/g of wet weight
tissue at room temperature for 24 h) and quantified at 620
nm with a Titerk Multiscan Microplate reader by compar-
ison with a standard curve of EB (0.5 to 25 µg/ml of for-
mamide). Extravasation was expressed as microgram of
EB per gram of dry tissue.
Statistical analysis
Differences between treatments were evaluated by one-
way ANOVA followed by the Bonferroni post-hoc test
(plasma extravasations studies) or by the Student t-test for
paired samples (for comparisons between right and left
cerebral hemispheres). Values were considered statisti-
cally significant when p < 0.05.
List of abbreviations used
BBB-Blood brain barrier
BK-Bradykinin
BTB-Blood tumor barrier
B1-Bradykinin receptor B1
B2-Bradykinin receptor B2
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LEU-[Leu8]-des-Arg9BK
MR-Metabolic resistance
PPE-Plasma protein extravasation
Protein plasma extravasation (PPE) in the right (C6-inocu-lated) and left (non-tumoral) hemisphere of ratsFigure 2
Protein plasma extravasation (PPE) in the right (C6-inocu-
lated) and left (non-tumoral) hemisphere of rats. The analysis 
was performed 17 days after the inoculations. PPE was signif-
icantly increased in the tumor hemisphere compared to the 
non-tumoral one. *p < 0.001 compared to PPE in the control 
(left) hemispheres.
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